Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in BRD4-NUTM1 NUT Carcinoma Harboring a BRD4 Splice Site Mutation.

[1]  G. Shapiro,et al.  BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial , 2022, Cancers.

[2]  S. Khochbin,et al.  NUT Is a Driver of p300-Mediated Histone Hyperacetylation: From Spermatogenesis to Cancer , 2022, Cancers.

[3]  W. Pierceall,et al.  A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma , 2020, British Journal of Cancer.

[4]  R. Plummer,et al.  First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours , 2020, British Journal of Cancer.

[5]  G. Shapiro,et al.  Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors , 2019, JNCI cancer spectrum.

[6]  S. Sallan,et al.  An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients , 2019, JNCI cancer spectrum.

[7]  Ying Cheng,et al.  Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302) , 2018, British Journal of Cancer.

[8]  P. D. Dal Cin,et al.  Ectopic protein interactions within BRD4–chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma , 2017, Proceedings of the National Academy of Sciences.

[9]  M. Kuroda,et al.  The Oncoprotein BRD4-NUT Generates Aberrant Histone Modification Patterns , 2016, PloS one.

[10]  P. Kharchenko,et al.  The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains , 2015, Genes & development.

[11]  J. Aster,et al.  MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma , 2014, Oncogene.

[12]  K. Carter,et al.  Novel BRD4–NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma , 2013, Oncogene.

[13]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[14]  T. Mahmoudi,et al.  Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription , 2007, Proceedings of the National Academy of Sciences.

[15]  Tom Misteli,et al.  The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  U. Kees,et al.  Intrathoracic carcinoma in an 11-year-old girl showing a translocation t(15;19). , 1991, The American journal of pediatric hematology/oncology.